Insider’s View: Deciphering Biogen Inc (BIIB)’s Financial Health Through Ratios

Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.

The price of Biogen Inc (NASDAQ: BIIB) closed at $221.50 in the last session, down -0.56% from day before closing price of $222.75. In other words, the price has decreased by -$0.56 from its previous closing price. On the day, 0.65 million shares were traded. BIIB stock price reached its highest trading level at $223.95 during the session, while it also had its lowest trading level at $220.01.


We take a closer look at BIIB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.32 and its Current Ratio is at 2.10. In the meantime, Its Debt-to-Equity ratio is 0.46 whereas as Long-Term Debt/Eq ratio is at 0.44.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on February 14, 2024, Reiterated its Buy rating but revised its target price to $300 from $305 previously.

On February 14, 2024, Wells Fargo Downgraded its rating to Equal Weight which previously was Overweight and also lowered its target price recommendation from $315 to $240.

UBS Downgraded its Buy to Neutral on January 24, 2024, whereas the target price for the stock was revised from $311 to $276.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 02 ’24 when Singhal Priya sold 93 shares for $213.09 per share. The transaction valued at 19,817 led to the insider holds 4,886 shares of the business.

Singhal Priya sold 262 shares of BIIB for $57,962 on Feb 22 ’24. The Head of Development now owns 4,886 shares after completing the transaction at $221.23 per share. On Feb 16 ’24, another insider, Singhal Priya, who serves as the Head of Development of the company, sold 108 shares for $221.49 each. As a result, the insider received 23,921 and left with 5,148 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BIIB now has a Market Capitalization of 32249733120 and an Enterprise Value of 38121910272. As of this moment, Biogen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 27.67, and their Forward P/E ratio for the next fiscal year is 12.69. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 8.65. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.47 while its Price-to-Book (P/B) ratio in mrq is 2.12. Its current Enterprise Value per Revenue stands at 3.945 whereas that against EBITDA is 15.129.

Stock Price History:

Over the past 52 weeks, BIIB has reached a high of $319.76, while it has fallen to a 52-week low of $189.44. The 50-Day Moving Average of the stock is 4.50%, while the 200-Day Moving Average is calculated to be -7.97%.

Shares Statistics:

According to the various share statistics, BIIB traded on average about 1.31M shares per day over the past 3-months and 1075560 shares per day over the past 10 days. A total of 144.90M shares are outstanding, with a floating share count of 144.43M. Insiders hold about 0.81% of the company’s shares, while institutions hold 91.03% stake in the company. Shares short for BIIB as of 1714435200 were 3147944 with a Short Ratio of 2.40, compared to 1711584000 on 3552970. Therefore, it implies a Short% of Shares Outstanding of 3147944 and a Short% of Float of 2.4400001000000002.

Most Popular

[the_ad id="945"]